Cerebral Palsy

Ensure the healthy future

Contact Us

Please fill in this form for additional information on treatment, procedures, price, etc.

About Treatment

Cerebral palsy is a term that unites a group of chronic diseases characterized by movement disorders. The main cause is abnormal development or damage of those parts of the brain that control movement, balance, and coordination. Often the problems develop during pregnancy, but they can also appear shortly after the birth or during childbirth. There are different types of cerebral palsy and the symptoms vary. Some of the patients experience difficulties with speech, eating and sleep. About 30%-50% people with cerebral palsy have mental development disorder. The prevalence rate of the disease is 2 to 1000 newborns (1,33 times more often among boys). There are many methods of cerebral palsy treatment, including medication and physiotherapy. Stem cell therapy is a relatively new method that has already shown positive results. Cellular treatment is based on the ability of stem cells to restore and build tissues in the organism. By implanting stem cells, doctors have managed to improve the functioning of organs and systems, particularly nervous and muscular. Stem cells contain programs and information which serve as an algorithm for correcting errors. It is important not to delay the treatment. The study shows, that children who undergo cellular treatment, develop faster than the children with the same diagnosis. Timely stem cell therapy allows recovering affected brain centers and nervous muscle control.

Improvements

Improvements that can be expected after stem cell therapy:

Improved function of the musculoskeletal system

Speech development

Prevention and elimination of seizures

Bowel and bladder control improvement

Cognitive function improvement

Consultation from a doctor for free

Get advice from a leading specialist and find out how stem cells will help you.

Reviews

Feedback on condition of I.C. suffering from cerebral palsy after the stem cell treatment

Patient: I.C.
Gender: Male
Age: 2
Diagnosis:Cerebral palsy with moderate left-sided hemiparesis
Country: USA

Dates of treatment: August 20-21, 2013.

Hello Valentina,

I. is doing well. He is finishing up 3 weeks of intensive therapy this Friday.

The changes we have noticed since stem therapy are as follows:

– I. is talking more, saying more words, and has better clarity when saying some words

– I. appears to be more actively engaged. By this, I mean that he giggles often and with much ease when someone says something silly or makes a silly sound. He has always been a happy boy, but he is laughing much more. He also has conversations with you – although most words one is unable to understand …

EmCell Clinic

Patient M.W. feedback on stem cell treatment at EmCell

Gender: Male
Age: 5
Country: USA
Diagnosis: Cerebral palsy with lower paraparesis. Mental and physical delay.

Hi!

Max is doing very well in general health. He is making more progress in motoric and fine movement. I have noticed that lately he is much more interested in toys, which he never done in the past. I hope he will make more improvement in the future.

Thank you and best regards.

M.

EmCell Clinic

Dartnell, Jo & Lee, Eng. (2015). Stem cell therapy in cerebral palsy. Current Orthopaedic Practice. 26. 15-20. 10.1097/BCO.0000000000000188.

Recent studies on the use of stem cells in cerebral palsy were reviewed. Most studies used either mesenchymal stem cells or umbilical cord stem cells. The main routes of administration were intravenous, intrathecal, or intraparenchymal. Animal studies were based on rodent models of hypoxia-ischemia encephalopathy and induced hypoxemia. The injections of cells were done acutely a few days after the brain insult. Results of animal studies were mixed. More mechanistic studies on how the stem cells contribute to repair are required. There were very few well-designed controlled clinical studies. Outcome measures were mainly based on functional recovery with only two studies using imaging. Results were mixed, with some studies showing early functional recovery in the younger children but this was not sustained. Imaging with PET/CT in one study showed differences in the pattern between the stem cell group and control group. There is a need for well-designed controlled studies with more objective outcome measures.

Paton, Madison & Mcdonald, Courtney & Allison, Beth & Fahey, Michael & Jenkin, Graham & Miller, Suzanne. (2017). Perinatal Brain Injury As a Consequence of Preterm Birth and Intrauterine Inflammation: Designing Targeted Stem Cell Therapies. Frontiers in Neuroscience. 11. 200. 10.3389/fnins.2017.00200.

Chorioamnionitis is a major cause of preterm birth and brain injury. Bacterial invasion of the chorion and amnion, and/or the placenta, can lead to a fetal inflammatory response, which in turn has significant adverse consequences for the developing fetal brain. Accordingly, there is a strong causal link between chorioamnionitis, preterm brain injury and the pathogenesis of severe postnatal neurological deficits and cerebral palsy. Currently there are no treatments to protect or repair against brain injury in preterm infants born after pregnancy compromised by intrauterine infection. This review describes the injurious cascade of events in the preterm brain in response to a severe fetal inflammatory event. We will highlight specific periods of increased vulnerability, and the potential effects of therapeutic intervention with cell-based therapies. Many clinical trials are underway to investigate the efficacy of stem cells to treat patients with cerebral palsy. Stem cells, obtained from umbilical cord tissue and cord blood, normally discarded after birth, are emerging as a safe and potentially effective therapy. It is not yet known, however, which stem cell type(s) are the most efficacious for administration to preterm infants to treat brain injury-mediated inflammation. Individual stem cell populations found in cord blood and tissue, such as mesenchymal stem cells (MSCs) and endothelial progenitor cells (EPCs), have a number of potential benefits that may specifically target preterm inflammatory-induced brain injury. MSCs have strong immunomodulatory potential, protecting against global and local neuroinflammatory cascades triggered during infection to the fetus. EPCs have angiogenic and vascular reparative qualities that make them ideal for neurovascular repair. A combined therapy using both MSCs and EPCs to target inflammation and promote angiogenesis for re-establishment of vital vessel networks is a treatment concept that warrants further investigation.